Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks
STANFORD HEALTH CARE, UCSF, & ORACLE
In oncology, biomarkers have many applications, including risk assessment, screening, differential diagnosis, determination of prognosis, response to treatment, and monitoring progression of the cancer. In this session we will highlight the current state of predictive biomarkers for oncology including recent successes, lessons learned, and challenges to come. Among the topics to be discussed are novel clinical trial designs for personalized medicine, emerging predictive biomarkers in immune-oncology trials, lessons learned from PD-L1 as an as an immunotherapy biomarker, and the path forward for next generation sequencing in cancer diagnostics.
Ann Kapoun, Ph.D., Vice President of Translational Medicine, Oncomed Pharmaceuticals
Ann Kapoun is Vice President of Translational Medicine at OncoMed Pharmaceuticals. Her expertise is in the clinical execution and implementation of biomarkers and patient stratification approaches. Dr. Kapoun served as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA / Johnson & Johnson. Read Full Bio
Laura Esserman, M.D., M.B.A., Director, Carol Franc Buck Breast Care Center, Professor of Surgery and Radiology, University of California, San Francisco, Associate Director, UCSF Helen Diller Family Comprehensive Cancer Center
Laura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment. Since 2002 she has led the I-SPY TRIALS, a groundbreaking national public-private collaboration among NCI, FDA, more than 20 cancer research centers and major pharma and biotech companies. Read Full Bio
Klaus Lindpaintner, M.D., MPH, FACP, Chief Scientific Officer, Thermo Fisher Scientific
Klaus Lindpaintner, MD, MPH, FACP serves as Chief Scientific Officer at Thermo Fisher Scientific, the world leader in oncology genomics companion testing products. Previously, he held senior positions at Hoffman-La Roche, where he spearheaded the company’s efforts in personalized health care. Read Full Bio
Raghu Kalluri, M.D., Ph.D., Chairmain & Professor, Dept. of Cancer Biology, MD Anderson
In 2015, Kalluri’s lab at MD Anderson received widespread attention for a discovery that could lead to a blood test that detects pancreatic cancer at an early stage, before it spreads to other organs and becomes too difficult to treat. Read Full Bio
Jeffrey Edward, Miller, Ph.D., CSO, CEO & Chairman, Invivoscribe, Inc.
Jeffrey Miller, Ph.D. has two decades of experience with personalized molecular medicine®. He founded Invivoscribe® in 1995 without outside investment. The company is a highly profitable vertically integrated international network of six wholly-owned ISO13485 manufacturing and ISO15189 clinical testing companies. Read Full Bio
Brad Gray, President & CEO, NanoString Techonologies
R. Bradley Gray has served as a member of the board of directors and as President and Chief Executive Officer since 2010. Prior to joining our company, Mr. Gray held various positions at Genzyme, a biotechnology company acquired by Sanofi in 2011. Read Full Bio
Ilan Kirsch, M.D., SVP, Translational Medicine, Adaptive Biotechnologies
Dr. Kirsch received his MD from Harvard University. He completed a 3-year post-doctoral fellowship in molecular genetics at the National Institute of Child Health and Human Development. Subsequently Dr. Read Full Bio
John West, CEO, Personalis, Inc.
Personalis’ CEO, John West, first became involved in DNA sequencing and DNA sequence interpretation in 1982. In the 1980’s, he led the development of an automated DNA sequencing system based on pattern recognition from autoradiographs, and licensed software from the lab of Roger Staden at MRC Cambridge, UK for sequence assembly and analysis. Read Full Bio
Christine M. Cournoyer, Chief Executive Officer, N-OF-ONE
Christine Cournoyer is CEO of N-of-One. Prior to N-of-One, she was President and COO of Picis, now a division of United Healthcare. At the time of acquisition, Picis systems were installed in more than 1,800 medical centers, hospitals, and IDNs in 19 countries. Read Full Bio